State Street Corp Increases Position in Twist Bioscience Co. (NASDAQ:TWST)

State Street Corp raised its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 19.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,167,353 shares of the company’s stock after purchasing an additional 526,028 shares during the quarter. State Street Corp owned 5.41% of Twist Bioscience worth $143,101,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth about $43,000. Blue Trust Inc. lifted its holdings in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the 2nd quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $47.50 on Friday. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -13.19 and a beta of 1.82. The company’s 50-day simple moving average is $44.94 and its two-hundred day simple moving average is $46.63. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 860 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the transaction, the senior vice president now owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 2,216 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $116,783.20. Following the transaction, the chief executive officer now directly owns 674,718 shares in the company, valued at $35,557,638.60. This trade represents a 0.33 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 101,787 shares of company stock valued at $4,584,508. Company insiders own 3.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TWST. Barclays lowered their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Scotiabank raised their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird lifted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $51.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.